AKTX Celsus Therapeutics PLC

Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid

Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid
EN
01/10/2020

Underlying

AKTXCelsus Therapeutics PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Celsus Therapeutics PLC

 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Nov...

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors Data presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor immunity through multiple mechanisms Treatment with a Trastuzumab-PH1 ADC monotherapy drove macrophages to polarize into an anti-tumor/inflammatory state and caused expa...

November 10, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Ta...

Akari Therapeutics’ Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th BOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced its abstract highlighting immune mechanism-of-action data for its novel ADC payload, PH1. The abstract is now available on the  website, and th...

November 4, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Announces Formation of Scientific Advisory Board an...

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the formation of its Scientific Advisory Board (SAB) and inaugural appointmen...

October 30, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Announces Launch of CEO Corner Platform

Akari Therapeutics Announces Launch of CEO Corner Platform CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for future videos Access the Akari CEO Corner BOSTON and LONDON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the launch of its featuring of Akari. The CEO Corner platform is intended to provide addit...

October 22, 2025 1 EN
 PRESS RELEASE
Free
AKTX Celsus Therapeu...

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Akari Therapeutics Announces $2.5 Million Registered Direct Offering BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000 of the Company’s American Depositary Shares (“ADSs”), each representing 2,000 ordinary shares at a purchase price of $0.80 per ADS in a registered direct offering. Ladenburg Thalmann & Co. Inc. is acting a...

October 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch